(BSX) Boston Scientific Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BSX) Boston Scientific Corporation Bundle
Actionable Strategy Starts Here
This Boston Scientific Corporation BCG Matrix helps you see how the company’s products or business units fit into the Stars, Cash Cows, Question Marks, and Dogs framework. The page already includes a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
FARAPULSE PFA, AF ablation
FARAPULSE is Boston Scientific Corporation’s clearest 2025 growth engine in electrophysiology: in Q1 2025, Electrophysiology sales jumped 124% reported to $493 million, driven by pulsed field ablation adoption. The platform is riding a fast-growing AF market, with FARAPULSE now a major launch engine across U.S. and international hospitals. High growth, strong procedure momentum, and expanding installed use fit a Star profile.
WATCHMAN FLX Pro, LAAC
WATCHMAN FLX Pro is a Star for Boston Scientific Corporation: it leads the left atrial appendage closure market, where stroke-prevention use is still expanding. In 2025, Boston Scientific kept funding clinical data, physician training, and launches in new markets to widen adoption. The franchise pairs scale, category leadership, and growth in a market where atrial fibrillation affects about 59 million people worldwide.
LithoVue, single-use ureteroscope
LithoVue fits a Stars profile because Boston Scientific Corporation is riding the move to single-use ureteroscopy in urology. The platform has a large installed base and each case drives repeat disposables, so demand stays tied to procedure volume, not just capital sales. That mix points to high share, strong growth, and durable follow-on revenue.
EP mapping and navigation tools
EP mapping and navigation tools stay a growth pocket for Boston Scientific because AF ablation demand is rising and FARAPULSE depends on a full workflow, not just a pulse generator. The global AF market is large: about 60 million people live with atrial fibrillation, and ablation use keeps climbing as centers add new energy platforms. This makes mapping and navigation strategically important, even if it is not the biggest sales line.
- Supports FARAPULSE adoption
- Benefits from AF ablation growth
- High strategic workflow value
EXALT Model D, single-use duodenoscope
EXALT Model D fits the "Star" slot in Boston Scientific Corporation's BCG Matrix: single-use duodenoscopy directly tackles infection-control and reprocessing risk, and the category is expanding faster than reusable endoscopy hardware. Boston Scientific said the Endoscopy business generated $4.3 billion in 2024 revenue, while single-use devices gain share as hospitals cut scope-reprocessing labor and cross-contamination exposure.
- Single-use duodenoscopy lowers reprocessing risk.
- Market growth outpaces reusable hardware.
- Boston Scientific is in a newer, faster-expanding segment.
Boston Scientific’s Growth Stars Are Driving Big Wins
Boston Scientific Corporation’s Stars are FARAPULSE, WATCHMAN FLX Pro, LithoVue, and EP mapping and navigation tools, because each combines high share with fast procedure growth. FARAPULSE drove Electrophysiology sales to $493 million in Q1 2025, up 124% reported. WATCHMAN addresses a 59 million-person AF pool, and Endoscopy revenue reached $4.3 billion in 2024, supporting EXALT Model D and LithoVue.
| Asset | Star signal | Key number |
|---|---|---|
| FARAPULSE | Fast adoption | $493M Q1 2025 EP sales |
| WATCHMAN FLX Pro | Leader in growth market | 59M AF patients |
| EXALT Model D | Single-use share gain | $4.3B Endoscopy revenue |
What is included in the product
Detailed Word Document
Boston Scientific’s BCG Matrix maps its devices by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG snapshot of Boston Scientific to spot winners, cash cows, and drag areas fast.
Reference Sources
Provides a clear source trail for Boston Scientific assumptions, boosting credibility and making decisions easier to verify.
Cash Cows
SYNERGY drug-eluting stents
SYNERGY drug-eluting stents sit in a mature coronary stent market with slower growth than newer procedural areas, but the franchise still monetizes a large installed base and recurring PCI demand. Boston Scientific keeps getting cash flow from repeat use in a market where coronary revascularization volumes remain high, so this is classic Cash Cow territory.
Core endoscopy disposables
Boston Scientific Corporation’s core endoscopy disposables fit Cash Cows because GI endoscopy accessories, biopsy tools, and hemostasis products are repeat-use items tied to procedure volume, not fast market growth. In fiscal 2025, Boston Scientific reported about $19.4 billion in net sales, and its Endoscopy business kept benefiting from steady demand in hospitals and ASCs. That makes these products reliable cash producers.
Peripheral artery intervention tools
Peripheral artery intervention tools fit Boston Scientific Corporation’s Cash Cow zone: stents, atherectomy, and related devices serve a mature vascular market, with broad commercial reach and steady replacement demand. The business should keep generating strong operating cash because pricing is stable and sales are less volatile than EP or LAAC. This makes it a dependable funding source for higher-growth franchises.
Urology consumables and access products
Urology consumables and access products are a cash cow for Boston Scientific Corporation because they sell with each procedure, so revenue repeats with case volume. In 2024, Boston Scientific Corporation reported $16.7 billion in net sales, and this mature line needs less launch spend than newer platforms, helping fund higher-growth bets.
- Repeat sales from procedure volume
- Lower launch spending than new platforms
- Strong cash support for growth bets
Legacy rhythm management hardware
Legacy rhythm management hardware is a cash cow for Boston Scientific Corporation: pacemakers and older ICD/CRT-D lines are mature, low-growth categories, but they still bring in steady cash from replacement cycles and service support. The upside is limited versus newer franchises, so this bucket is mainly about protecting margin and funding faster-growing areas.
- Steady replacements support cash flow
- Service revenue adds recurring income
- Growth lags newer Boston Scientific lines
Boston Scientific’s Cash Cows Keep the Cash Flowing in 2025
Boston Scientific Corporation’s Cash Cows are mature, repeat-use lines like SYNERGY stents, endoscopy disposables, peripheral tools, urology consumables, and legacy rhythm devices. In fiscal 2025, Boston Scientific Corporation reported $19.4 billion in net sales, and these franchises kept producing cash from high procedure volume and replacement demand. They need less launch spend, so they help fund faster-growth areas.
| Cash Cow line | Why it fits | FY2025 signal |
|---|---|---|
| SYNERGY stents | Mature PCI market | Steady repeat demand |
| Endoscopy disposables | Procedure-linked sales | Recurring hospital use |
| Urology consumables | Use per case | Low launch spend |
Get Your Copy
Boston Scientific Corporation Reference Sources
This Boston Scientific Corporation BCG Matrix preview is the exact same document you’ll receive after purchase. No placeholders, no watermark—just the full, professionally formatted file. You can use it right away for analysis, planning, or presentation. What you see here is what you get.
Dogs
Legacy bare-metal coronary stents
Legacy bare-metal coronary stents are a Dogs category for Boston Scientific Corporation: older formats sit in a low-growth market and have been displaced by drug-eluting stents, which now dominate PCI care. This line is a shrinking, low-single-digit share of the portfolio, while newer cardiovascular products drive most growth. Low demand and weak pricing make it a low-return asset.
Older diagnostic EP catheters
Boston Scientific Corporation’s older diagnostic EP catheters fit the Dog box: in 2025-2026, newer mapping, imaging, and pulsed field ablation (PFA) workflows took the lead, so these legacy tools are no longer the main EP growth driver.
That shift matters because PFA is scaling fast, while traditional diagnostic catheters face weak relative share and low category growth.
For Boston Scientific, the smarter capital goes to higher-growth EP platforms, not aging catheter lines.
Conventional CRT-D systems
Boston Scientific Corporation’s conventional CRT-D systems sit in a mature, highly competitive heart-failure device market, where global heart failure affects about 64 million people and replacement demand is steadier than new growth. Their legacy CRT-D line lacks the faster expansion seen in Boston Scientific Corporation’s newer rhythm franchises, so it fits a low-growth, low-share profile. In BCG terms, that points closer to a Dog than a Star.
Low-growth pacemaker variants
Boston Scientific Corporation’s standard pacemaker line fits the Dogs bucket because it is a mature, low-growth niche that mostly depends on replacement demand, while newer EP and LAAC products drive the company’s growth. In 2025, Boston Scientific Corporation reported net sales of about $16.7 billion, showing that pacemakers are not the main expansion engine. These units are usually cash-neutral, not a big source of incremental upside.
- Mature market, slow organic growth
- Mostly replacement-driven demand
- Outpaced by EP and LAAC
- Cash-neutral, not a growth driver
Legacy neuromodulation implants
Boston Scientific Corporation’s legacy neuromodulation implants fit a Dog profile: older pain and stimulation systems have been overshadowed by newer platforms and tougher rivals, so growth and pricing power are weak. In 2025, Boston Scientific generated about $16.7 billion in net sales, but this older niche lacks the scale and momentum of the company’s faster-growing categories.
- Older systems face weaker differentiation.
- New launches and rivals take share.
- Growth stays limited versus top franchises.
- Low momentum supports Dog status.
Boston Scientific’s Legacy Devices Lag While New Therapies Drive Growth
Boston Scientific Corporation's Dogs are legacy lines in slow or shrinking niches: bare-metal stents, older EP catheters, standard pacemakers, CRT-D, and older neuromodulation. In 2025, net sales were about $16.7 billion, but these units were not the growth engine. Newer platforms like PFA and other advanced therapies took share and capital. They fit low-growth, low-share roles.
| Dog line | Why it fits |
|---|---|
| Legacy devices | Low growth, weak pricing |
| 2025 net sales | $16.7 billion |
Question Marks
AGENT drug-coated balloon
AGENT is a Question Mark in Boston Scientific Corporation’s BCG matrix: it targets coronary in-stent restenosis, a meaningful but still early market, and the device won U.S. FDA approval in April 2024. That gives Boston Scientific a chance to build share, but adoption is still not proven at scale. The upside is real, yet near-term volume and profit contribution remain uncertain.
ACURATE neo2 transcatheter valve
ACURATE neo2 sits in Question Marks: structural heart is still a large, growing market, but Boston Scientific is not yet as dominant here as in EP or LAAC. The valve has strategic option value outside the U.S., where TAVR demand keeps rising and Boston Scientific can still win share. Growth upside is real, but share remains uncertain, so this is a high-potential, high-risk bet.
Deep brain stimulation systems
Deep brain stimulation systems are a Question Mark for Boston Scientific Corporation: neuromodulation is growing, but DBS is still a 3-horse race against Medtronic and Abbott. In 2025, Boston Scientific had a much larger total sales base, yet DBS needs faster share gains and proof of scale before it deserves heavier capital. The market is attractive, but the ROI case is not proven.
Venous thrombectomy and thrombolysis systems
Venous thrombectomy and thrombolysis systems sit in a fast-growing but still early category, so Boston Scientific Corporation is more in share-building mode than in harvest mode. The business matters because clot-removal adoption is rising, but it is still far smaller than Boston Scientific Corporation's core franchises.
- Growth area, not a core profit engine
- Adoption is still uneven
- Winning share is the main task
Boston Scientific Corporation participates, but the platform is still developing relative to its larger cardiovascular and electrophysiology businesses. That makes execution and hospital penetration more important than near-term scale.
Interventional oncology expansion
Interventional oncology is a Question Mark for Boston Scientific Corporation: embolization and ablation can grow fast, but the unit still lacks clear company-wide share leadership. Boston Scientific’s 2025 focus on selective capital and trial-backed product wins matters, because this space rewards scale and strong clinical data more than broad brand power.
- High growth, still weak share
- Best backed by selective R&D
- Drift risk if spend is too thin
Boston Scientific’s Growth Bets: Early Wins, No Durable Scale Yet
Boston Scientific Corporation’s Question Marks are AGENT, ACURATE neo2, deep brain stimulation, venous thrombectomy/thrombolysis, and interventional oncology. These are growth bets, but none has proven durable scale yet; AGENT’s U.S. FDA approval came in Apr 2024, while the rest still face uneven adoption and share gaps in 2025.
| Area | 2025/2026 signal | Status |
|---|---|---|
| AGENT | FDA Apr 2024 | Early share build |
| DBS | 3-way rivalry | Scale not proven |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.